文献速递肿瘤 PET/CT核素与放射性配体治疗

[18F]FDG与PSMA-PET在转移性去势抵抗性前列腺癌患者[177Lu]Lu-PSMA治疗评估中的预后价值

Prognostic value of [18F]FDG- and PSMA-PET in patients evaluated for [177Lu]Lu-PSMA therapy of mCRPC.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-03-21

回顾性分析152例考虑接受[177Lu]Lu-PSMA治疗的mCRPC患者,其中104例(68.4%)接受LuPSMA治疗,48例(31.6%)接受其他标准治疗。基线[18F]FDG总肿瘤体积是两组总生存期的独立预测因子;PSMA-PET SUVmean与LuPSMA治疗后PSA下降≥50%相关。作者认为双示踪剂显像应在前瞻性试验中进一步评估用于mCRPC治疗指导。

要点

  • 基线[18F]FDG总肿瘤体积是LuPSMA组和其他标准治疗组总生存期的独立预测因子。
  • PSMA-PET SUVmean是LuPSMA治疗后PSA下降≥50%的独立预测因子(OR 2.97)。
  • 作者建议双示踪剂显像应在前瞻性试验中进一步评估用于mCRPC治疗指导。

核心结论

  • PSMA-PET和[18F]FDG-PET为LuPSMA候选患者提供结局的影像生物标志物。
  • FDG-PET总肿瘤体积是LuPSMA治疗候选者总生存期的独立预测因子,与后续治疗决策无关。
  • PSMA-PET SUVmean与LuPSMA的生化反应相关。
  • 作者建议双示踪剂显像应在前瞻性试验中进一步评估用于mCRPC治疗指导。

研究设计与样本

  • 回顾性分析152例转诊接受LuPSMA治疗的mCRPC患者,均行PSMA和[18F]FDG-PET/CT。
  • 104例(68.4%)接受LuPSMA治疗,48例(31.6%)接受其他标准治疗。
  • PET/CT分析包括视觉评估和半定量测量,记录临床和实验室参数。
  • 主要终点为总生存期,次要终点为PSA反应(下降>50%)。

主要发现

  • 基线[18F]FDG总肿瘤体积是LuPSMA组总生存期的独立预测因子(HR 1.28 [95%CI 1.02-1.61];p=0.03)。
  • 基线[18F]FDG总肿瘤体积也是其他标准治疗组总生存期的独立预测因子(HR 1.61 [95%CI 1.02-2.56];p=0.04)。
  • 其他标准治疗组总生存期的其他独立预测因子包括PSMA总病变摄取(PSMA-TL;HR 1.14 [95%CI 1.03-1.26];p=0.01)、[18F]FDG平均SUV(HR 20.88 [95%CI 1.2-364.74];p=0.04)和[18F]FDG总病变糖酵解(HR 1.61 [95%CI 1.02-2.56];p=0.04)。
  • LuPSMA组中,PSMA-PET SUVmean是PSA下降≥50%的显著独立预测因子(OR 2.97 [95%CI 1.27-8.16];p=0.02)。

关键数值与推荐

  • 基线[18F]FDG总肿瘤体积预测LuPSMA组总生存期:HR 1.28(95%CI 1.02-1.61;p=0.03)。
  • 基线[18F]FDG总肿瘤体积预测其他标准治疗组总生存期:HR 1.61(95%CI 1.02-2.56;p=0.04)。
  • 其他标准治疗组总生存期预测:PSMA-TL HR 1.14(95%CI 1.03-1.26;p=0.01);[18F]FDG平均SUV HR 20.88(95%CI 1.2-364.74;p=0.04);[18F]FDG总病变糖酵解 HR 1.61(95%CI 1.02-2.56;p=0.04)。
  • LuPSMA组PSA下降≥50%预测:PSMA-PET SUVmean OR 2.97(95%CI 1.27-8.16;p=0.02)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To improve [177Lu]Lu-Prostate-specific membrane antigen therapy (LuPSMA) selection, this study investigates the prognostic value of PSMA and 2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG)-PET in metastatic castration-resistant prostate cancer (mCRPC) patients considered for LuPSMA therapy. METHODS: We conducted a retrospective analysis in 152 mCRPC patients referred for LuPSMA therapy who underwent PSMA and [18F]FDG-PET/CT. Of these, 104 patients (68.4%) underwent LuPSMA therapy, while 48 (31.6%) received other standard of care (SOC). PET/CT analyses included visual assessment and semiquantitative measurements. Clinical and laboratory parameters were recorded. Overall survival (OS) and PSA response (decline > 50%) were primary and secondary endpoints, respectively. RESULTS: Baseline [18F]FDG-derived total tumor volume was the only independent predictor of overall survival both in patients subsequently treated with LuPSMA (HR 1.28 [95%CI 1.02-1.61]; p = 0.03) or in those under other SOC (HR 1.61 [95%CI 1.02-2.56]; p = 0.04), respectively. In other SOC patients, additional independent predictors of OS were total lesion PSMA uptake (PSMA-TL; HR 1.14 [95%CI 1.03-1.26]; p = 0.01), [18F]FDG mean SUV (HR 20.88 [95%CI 1.2-364.74]; p = 0.04), and [18F]FDG total lesion glycolysis (HR 1.61 [95%CI 1.02-2.56]; p = 0.04). In LuPSMA patients, PSMA-PET SUVmean was a significant independent predictor of PSA decline ≥ 50% (OR 2.97 [95%CI 1.27-8.16]; p = 0.02). CONCLUSION: PSMA-PET and [18F]FDG-PET provide imaging biomarkers of outcome in candidates for LuPSMA. FDG-PET total tumor volume was an independent predictor of overall survival in candidates for LuPSMA therapy, irrespective of subsequent treatment decision. PSMA-PET SUVmean was associated with biochemical response to LuPSMA. Dual tracer imaging should further be assessed in prospective trials for mCRPC treatment guidance.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Telli T, Lopes L, Karpinski M, et al. Prognostic value of [18F]FDG- and PSMA-PET in patients evaluated for [177Lu]Lu-PSMA therapy of mCRPC. Eur J Nucl Med Mol Imaging. 2025. PMID: 40113645. doi:10.1007/s00259-025-07198-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。